drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00490 | DB00835 | 946 | 100 | [
"DDInter254",
"DDInter245"
] | Buspirone | Brompheniramine | Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT<sub>1A</sub> receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic dr... | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
946,
24,
100
]
],
[
[
946,
24,
832
],
[
832,
24,
100
]
],
[
[
946,
63,
128
],
[
128,
24,
100
]
],
[
[
946,
24,
649
],
[
649,
63,... | [
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],
... | Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Dexbromphe... |
DB00649 | DB00916 | 231 | 112 | [
"DDInter1710",
"DDInter1202"
] | Stavudine | Metronidazole | A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Moderate | 1 | [
[
[
231,
24,
112
]
],
[
[
231,
24,
458
],
[
458,
40,
112
]
],
[
[
231,
21,
28692
],
[
28692,
60,
112
]
],
[
[
231,
63,
322
],
[
322,
... | [
[
[
"Stavudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
]
],
[
[
"Stavudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinidazole"
],
[
... | Stavudine may cause a moderate interaction that could exacerbate diseases when taken with Tinidazole and Tinidazole (Compound) resembles Metronidazole (Compound)
Stavudine (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Metronidazole (Compound)
Stavudine may cause a modera... |
DB00687 | DB04861 | 870 | 1,592 | [
"DDInter747",
"DDInter1271"
] | Fludrocortisone | Nebivolol | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and... | Moderate | 1 | [
[
[
870,
24,
1592
]
],
[
[
870,
21,
28762
],
[
28762,
60,
1592
]
],
[
[
870,
23,
1283
],
[
1283,
23,
1592
]
],
[
[
870,
24,
1479
],
[
1479... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nebivolol"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) ... | Fludrocortisone (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Nebivolol (Compound)
Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide and Magnesium oxide may cause a minor interaction that can limit clinical effects when taken... |
DB00951 | DB01261 | 1,072 | 170 | [
"DDInter986",
"DDInter1679"
] | Isoniazid | Sitagliptin | Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Moderate | 1 | [
[
[
1072,
24,
170
]
],
[
[
1072,
6,
3486
],
[
3486,
45,
170
]
],
[
[
1072,
21,
28792
],
[
28792,
60,
170
]
],
[
[
1072,
24,
52
],
[
52,
... | [
[
[
"Isoniazid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Isoniazid",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
... | Isoniazid (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Sitagliptin (Compound)
Isoniazid (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Sitagliptin (Compound)
Isoniazid may cause a moderate interaction that could exacerbate diseases when... |
DB00728 | DB01190 | 1,610 | 568 | [
"DDInter1612",
"DDInter398"
] | Rocuronium | Clindamycin | Rocuronium (rapid onset-curonium) is a desacetoxy analogue of vecuronium with a more rapid onset of action. It is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechan... | Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms[L11599,L11596] as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bac... | Moderate | 1 | [
[
[
1610,
24,
568
]
],
[
[
1610,
21,
28680
],
[
28680,
60,
568
]
],
[
[
1610,
25,
1132
],
[
1132,
24,
568
]
],
[
[
1610,
1,
728
],
[
728,
... | [
[
[
"Rocuronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clindamycin"
]
],
[
[
"Rocuronium",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v}... | Rocuronium (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Clindamycin (Compound)
Rocuronium may lead to a major life threatening interaction when taken with Gentamicin and Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Clindamycin
Rocuronium (Compoun... |
DB00518 | DB00877 | 510 | 629 | [
"DDInter35",
"DDInter1678"
] | Albendazole | Sirolimus | A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38) | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Moderate | 1 | [
[
[
510,
24,
629
]
],
[
[
510,
6,
4973
],
[
4973,
45,
629
]
],
[
[
510,
18,
10643
],
[
10643,
46,
629
]
],
[
[
510,
7,
8155
],
[
8155,
... | [
[
[
"Albendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Albendazole",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Albendazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sirolimus (Compound)
Albendazole (Compound) downregulates EAPP (Gene) and EAPP (Gene) is upregulated by Sirolimus (Compound)
Albendazole (Compound) upregulates ABCC5 (Gene) and ABCC5 (Gene) is upregulated by Sirolimus (Compound)
Albendazole (Compoun... |
DB00275 | DB12941 | 217 | 466 | [
"DDInter1330",
"DDInter481"
] | Olmesartan | Darolutamide | Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes [telmisartan], [candesartan], [losartan], [valsartan], and [irbesartan]. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, w... | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate canc... | Moderate | 1 | [
[
[
217,
24,
466
]
],
[
[
217,
24,
484
],
[
484,
23,
466
]
],
[
[
217,
24,
72
],
[
72,
24,
466
]
],
[
[
217,
24,
412
],
[
412,
25,
... | [
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]
],
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[... | Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag and Elt... |
DB00434 | DB00771 | 13 | 262 | [
"DDInter459",
"DDInter397"
] | Cyproheptadine | Clidinium | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | Moderate | 1 | [
[
[
13,
24,
262
]
],
[
[
13,
40,
11286
],
[
11286,
1,
262
]
],
[
[
13,
24,
1511
],
[
1511,
63,
262
]
],
[
[
13,
6,
2720
],
[
2720,
4... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clidinium"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) resembles {v} (Compound)",
"Diphenylpyraline"
],
[
"Diphenylpyraline",
"{u} ... | Cyproheptadine (Compound) resembles Diphenylpyraline (Compound) and Diphenylpyraline (Compound) resembles Clidinium (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when t... |
DB11652 | DB12010 | 1,155 | 214 | [
"DDInter1891",
"DDInter785"
] | Tucatinib | Fostamatinib | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
1155,
24,
214
]
],
[
[
1155,
64,
976
],
[
976,
24,
214
]
],
[
[
1155,
63,
723
],
[
723,
24,
214
]
],
[
[
1155,
24,
738
],
[
738,
... | [
[
[
"Tucatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Tucatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitin... | Tucatinib may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may caus... |
DB01191 | DB08907 | 1,039 | 1,344 | [
"DDInter518",
"DDInter280"
] | Dexfenfluramine | Canagliflozin | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
1039,
24,
1344
]
],
[
[
1039,
24,
549
],
[
549,
1,
1344
]
],
[
[
1039,
63,
176
],
[
176,
24,
1344
]
],
[
[
1039,
25,
1399
],
[
1399,
... | [
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"... | Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a ... |
DB01619 | DB09488 | 830 | 103 | [
"DDInter1441",
"DDInter23"
] | Phenindamine | Acrivastine | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine ... | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema,... | Moderate | 1 | [
[
[
830,
24,
103
]
],
[
[
830,
23,
771
],
[
771,
62,
103
]
],
[
[
830,
63,
1405
],
[
1405,
24,
103
]
],
[
[
830,
24,
573
],
[
573,
2... | [
[
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Phenindamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
],
... | Phenindamine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Acrivastine
Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprin... |
DB00515 | DB06688 | 589 | 1,430 | [
"DDInter387",
"DDInter1677"
] | Cisplatin | Sipuleucel-T | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Moderate | 1 | [
[
[
589,
24,
1430
]
],
[
[
589,
24,
175
],
[
175,
24,
1430
]
],
[
[
589,
25,
869
],
[
869,
24,
1430
]
],
[
[
589,
25,
676
],
[
676,
... | [
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[... | Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Cisplatin may lead to a major life threatening interaction when taken with Topotecan and Topotecan may ca... |
DB00619 | DB01097 | 1,419 | 1,377 | [
"DDInter909",
"DDInter1033"
] | Imatinib | Leflunomide | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
1419,
25,
1377
]
],
[
[
1419,
6,
6017
],
[
6017,
45,
1377
]
],
[
[
1419,
21,
29062
],
[
29062,
60,
1377
]
],
[
[
1419,
24,
949
],
[
94... | [
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Imatinib",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Leflunomid... | Imatinib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Leflunomide (Compound)
Imatinib (Compound) causes Neutropenia (Side Effect) and Neutropenia (Side Effect) is caused by Leflunomide (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani ... |
DB00844 | DB04843 | 314 | 1,511 | [
"DDInter1257",
"DDInter1149"
] | Nalbuphine | Mepenzolate | A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States. | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Moderate | 1 | [
[
[
314,
24,
1511
]
],
[
[
314,
24,
537
],
[
537,
24,
1511
]
],
[
[
314,
63,
262
],
[
262,
24,
1511
]
],
[
[
314,
24,
649
],
[
649,
... | [
[
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
... | Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Clidiniu... |
DB00008 | DB06688 | 491 | 1,430 | [
"DDInter1407",
"DDInter1677"
] | Peginterferon alfa-2a | Sipuleucel-T | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Moderate | 1 | [
[
[
491,
24,
1430
]
],
[
[
491,
24,
869
],
[
869,
24,
1430
]
],
[
[
491,
25,
676
],
[
676,
63,
1430
]
],
[
[
491,
24,
310
],
[
310,
... | [
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Top... | Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Peginterferon alfa-2a may lead to a major life threatening interaction when taken with Upadacitinib a... |
DB00757 | DB01156 | 1,166 | 593 | [
"DDInter581",
"DDInter252"
] | Dolasetron | Bupropion | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Major | 2 | [
[
[
1166,
25,
593
]
],
[
[
1166,
6,
8374
],
[
8374,
45,
593
]
],
[
[
1166,
21,
28757
],
[
28757,
60,
593
]
],
[
[
1166,
62,
752
],
[
752,
... | [
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
]
],
[
[
"Dolasetron",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Bupropio... | Dolasetron (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bupropion (Compound)
Dolasetron (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Bupropion (Compound)
Dolasetron may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidi... |
DB09054 | DB12301 | 384 | 907 | [
"DDInter905",
"DDInter585"
] | Idelalisib | Doravirine | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Doravirine is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) intended to be administered in combination with other antiretroviral medicines.[L12729,L4562] Doravirine is available by itself or as a combination product of doravirine (100 mg), lamivudine (300 mg), and tenofovir disoproxil fumarate (300 mg... | Minor | 0 | [
[
[
384,
23,
907
]
],
[
[
384,
64,
1478
],
[
1478,
23,
907
]
],
[
[
384,
25,
159
],
[
159,
62,
907
]
],
[
[
384,
25,
951
],
[
951,
2... | [
[
[
"Idelalisib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doravirine"
]
],
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
... | Idelalisib may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Doravirine
Idelalisib may lead to a major life threatening interaction when taken with Larotrectinib and Larotrectinib may cause a minor inter... |
DB01166 | DB14357 | 477 | 944 | [
"DDInter379",
"DDInter347"
] | Cilostazol | Chamomile | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Chamomile is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug. | Minor | 0 | [
[
[
477,
23,
944
]
],
[
[
477,
24,
256
],
[
256,
23,
944
]
],
[
[
477,
63,
582
],
[
582,
23,
944
]
],
[
[
477,
25,
792
],
[
792,
23,... | [
[
[
"Cilostazol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
],
[
... | Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Chamomile
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Reteplase and Reteplase ma... |
DB00356 | DB00366 | 1,315 | 1,594 | [
"DDInter366",
"DDInter600"
] | Chlorzoxazone | Doxylamine | A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202) | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Moderate | 1 | [
[
[
1315,
24,
1594
]
],
[
[
1315,
24,
662
],
[
662,
63,
1594
]
],
[
[
1315,
21,
29081
],
[
29081,
60,
1594
]
],
[
[
1315,
64,
475
],
[
475... | [
[
[
"Chlorzoxazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
]
],
[
[
"Chlorzoxazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],... | Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine
Chlorzoxazone (Compound) causes Angioedema (Side Effect) and Angioedema (Side Effect) is caused by Doxy... |
DB00468 | DB05294 | 1,424 | 1,069 | [
"DDInter1557",
"DDInter1917"
] | Quinine | Vandetanib | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Major | 2 | [
[
[
1424,
25,
1069
]
],
[
[
1424,
6,
8374
],
[
8374,
45,
1069
]
],
[
[
1424,
21,
28883
],
[
28883,
60,
1069
]
],
[
[
1424,
23,
1135
],
[
1... | [
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
]
],
[
[
"Quinine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Vandetanib"
... | Quinine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vandetanib (Compound)
Quinine (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Vandetanib (Compound)
Quinine may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxego... |
DB00029 | DB00861 | 25 | 914 | [
"DDInter99",
"DDInter551"
] | Anistreplase | Diflunisal | Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl gro... | Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear ... | Moderate | 1 | [
[
[
25,
24,
914
]
],
[
[
25,
25,
1564
],
[
1564,
63,
914
]
],
[
[
25,
24,
1061
],
[
1061,
24,
914
]
],
[
[
25,
25,
366
],
[
366,
24,... | [
[
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diflunisal"
]
],
[
[
"Anistreplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
],
[
"Defib... | Anistreplase may lead to a major life threatening interaction when taken with Defibrotide and Defibrotide may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal
Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil ... |
DB01035 | DB11110 | 1,401 | 603 | [
"DDInter1524",
"DDInter1115"
] | Procainamide | Magnesium citrate | A derivative of procaine with less CNS action. | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Moderate | 1 | [
[
[
1401,
24,
603
]
],
[
[
1401,
25,
57
],
[
57,
24,
603
]
],
[
[
1401,
36,
1151
],
[
1151,
24,
603
]
],
[
[
1401,
25,
484
],
[
484,
... | [
[
[
"Procainamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
... | Procainamide may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Procainamide (Compound) resembles Sunitinib (Compound) and Procainamide may lead to a major life threateni... |
DB00631 | DB00827 | 372 | 646 | [
"DDInter405",
"DDInter383"
] | Clofarabine | Cinoxacin | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections. | Minor | 0 | [
[
[
372,
23,
646
]
],
[
[
372,
21,
28691
],
[
28691,
60,
646
]
],
[
[
372,
24,
77
],
[
77,
62,
646
]
],
[
[
372,
63,
322
],
[
322,
2... | [
[
[
"Clofarabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cinoxacin"
]
],
[
[
"Clofarabine",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Effect) is cau... | Clofarabine (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Cinoxacin (Compound)
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin may cause a minor interaction that can limit clinical effects when taken with Cinoxa... |
DB00231 | DB00507 | 1,174 | 316 | [
"DDInter1761",
"DDInter1299"
] | Temazepam | Nitazoxanide | Temazepam, like many other similar and related benzodiazepines, acts as a gamma-aminobutyric acid (GABA) modulator and is capable of eliciting a variety of actions including sedation, hypnosis, skeletal muscle relaxation, anticonvulsant activity, and anxiolytic action [A175207, A175210, F3718, F3721]. Although the chem... | Nitazoxanide belongs to the class of drugs known as _thiazolides_. Nitazoxanide (NTZ) is a broad-spectrum anti-infective drug that markedly modulates the survival, growth, and proliferation of a range of extracellular and intracellular protozoa, helminths, anaerobic and microaerophilic bacteria, in addition to viruses.... | Moderate | 1 | [
[
[
1174,
24,
316
]
],
[
[
1174,
21,
28779
],
[
28779,
60,
316
]
],
[
[
1174,
1,
481
],
[
481,
63,
316
]
],
[
[
1174,
24,
608
],
[
608,
... | [
[
[
"Temazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitazoxanide"
]
],
[
[
"Temazepam",
"{u} (Compound) causes {v} (Side Effect)",
"Dry mouth"
],
[
"Dry mouth",
"{u} (Side Effect) is caus... | Temazepam (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Nitazoxanide (Compound)
Temazepam (Compound) resembles Quazepam (Compound) and Quazepam may cause a moderate interaction that could exacerbate diseases when taken with Nitazoxanide
Temazepam may cause a moderate interaction tha... |
DB00328 | DB06228 | 831 | 792 | [
"DDInter921",
"DDInter1609"
] | Indomethacin | Rivaroxaban | Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlor... | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Major | 2 | [
[
[
831,
25,
792
]
],
[
[
831,
6,
4973
],
[
4973,
45,
792
]
],
[
[
831,
21,
28703
],
[
28703,
60,
792
]
],
[
[
831,
23,
752
],
[
752,
... | [
[
[
"Indomethacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Indomethacin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Riva... | Indomethacin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Rivaroxaban (Compound)
Indomethacin (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Rivaroxaban (Compound)
Indomethacin may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Ci... |
DB01045 | DB12010 | 463 | 214 | [
"DDInter1590",
"DDInter785"
] | Rifampicin | Fostamatinib | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Major | 2 | [
[
[
463,
25,
214
]
],
[
[
463,
25,
976
],
[
976,
24,
214
]
],
[
[
463,
63,
723
],
[
723,
24,
214
]
],
[
[
463,
1,
690
],
[
690,
24,
... | [
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
]
],
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{... | Rifampicin may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may ca... |
DB05812 | DB08903 | 1,374 | 996 | [
"DDInter8",
"DDInter170"
] | Abiraterone | Bedaquiline | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Major | 2 | [
[
[
1374,
25,
996
]
],
[
[
1374,
63,
1376
],
[
1376,
1,
996
]
],
[
[
1374,
6,
8374
],
[
8374,
45,
996
]
],
[
[
1374,
21,
29282
],
[
29282,... | [
[
[
"Abiraterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
],
[
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Di... | Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Bedaquiline (Compound)
Abiraterone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bedaquiline (Compound)
Abiraterone (Compound) causes Arrhythmia (Side Effec... |
DB00681 | DB09133 | 1,287 | 1,527 | [
"DDInter85",
"DDInter965"
] | Amphotericin B | Iothalamic acid | Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphot... | Iothalamic acid is an iodine containing organic anion used as a diagnostic contrast agent. | Major | 2 | [
[
[
1287,
25,
1527
]
],
[
[
1287,
24,
1577
],
[
1577,
24,
1527
]
],
[
[
1287,
64,
228
],
[
228,
24,
1527
]
],
[
[
1287,
63,
1028
],
[
1028... | [
[
[
"Amphotericin B",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iothalamic acid"
]
],
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroflumethiazide"
],
... | Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide and Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid
Amphotericin B may lead to a major life threatening interaction when taken with Dofetil... |
DB00290 | DB00445 | 329 | 322 | [
"DDInter219",
"DDInter655"
] | Bleomycin | Epirubicin | A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin. | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Moderate | 1 | [
[
[
329,
24,
322
]
],
[
[
329,
5,
11555
],
[
11555,
44,
322
]
],
[
[
329,
21,
28719
],
[
28719,
60,
322
]
],
[
[
329,
23,
646
],
[
646,
... | [
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
]
],
[
[
"Bleomycin",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease)... | Bleomycin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Epirubicin (Compound)
Bleomycin (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Epirubicin (Compound)
Bleomycin may cause a minor interaction that can limit clinical effects when taken with C... |
DB00641 | DB06273 | 467 | 980 | [
"DDInter1675",
"DDInter1824"
] | Simvastatin | Tocilizumab | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endog... | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Moderate | 1 | [
[
[
467,
24,
980
]
],
[
[
467,
62,
1428
],
[
1428,
24,
980
]
],
[
[
467,
63,
139
],
[
139,
24,
980
]
],
[
[
467,
24,
309
],
[
309,
2... | [
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
]
],
[
[
"Simvastatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Isradipine"
],
[
... | Simvastatin may cause a minor interaction that can limit clinical effects when taken with Isradipine and Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidov... |
DB00214 | DB00675 | 1,028 | 888 | [
"DDInter1836",
"DDInter1744"
] | Torasemide | Tamoxifen | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Moderate | 1 | [
[
[
1028,
24,
888
]
],
[
[
1028,
24,
1376
],
[
1376,
64,
888
]
],
[
[
1028,
6,
10215
],
[
10215,
45,
888
]
],
[
[
1028,
18,
3439
],
[
3439... | [
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
... | Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may lead to a major life threatening interaction when taken with Tamoxifen
Torasemide (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Tamoxifen (Compound)
Torasemide (Compound) d... |
DB00518 | DB09420 | 510 | 1,074 | [
"DDInter35",
"DDInter953"
] | Albendazole | Iodide I-123 | A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38) | Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect t... | Moderate | 1 | [
[
[
510,
24,
1074
]
],
[
[
510,
23,
1220
],
[
1220,
24,
1074
]
],
[
[
510,
1,
1370
],
[
1370,
24,
1074
]
],
[
[
510,
23,
1220
],
[
1220,
... | [
[
[
"Albendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Albendazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
],
... | Albendazole may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Albendazole (Compound) resembles Mebendazole (Compound) and Mebendazole may cause a moderate interaction ... |
DB00675 | DB01208 | 888 | 945 | [
"DDInter1744",
"DDInter1705"
] | Tamoxifen | Sparfloxacin | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Major | 2 | [
[
[
888,
25,
945
]
],
[
[
888,
24,
739
],
[
739,
1,
945
]
],
[
[
888,
64,
1176
],
[
1176,
1,
945
]
],
[
[
888,
25,
246
],
[
246,
1,
... | [
[
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sparfloxacin"
]
],
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
],
[
"Lomeflox... | Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Sparfloxacin (Compound)
Tamoxifen may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Sparfloxacin (Compound)
Tamox... |
DB00092 | DB09330 | 58 | 985 | [
"DDInter40",
"DDInter1352"
] | Alefacept | Osimertinib | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Moderate | 1 | [
[
[
58,
24,
985
]
],
[
[
58,
24,
168
],
[
168,
23,
985
]
],
[
[
58,
24,
134
],
[
134,
24,
985
]
],
[
[
58,
24,
119
],
[
119,
63,
... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelb... |
DB01089 | DB09112 | 1,340 | 1,455 | [
"DDInter502",
"DDInter1306"
] | Deserpidine | Nitrous acid | Deserpidine is an ester alkaloid drug isolated from Rauwolfia canescens (family Apocynaceae) with antipsychotic and antihypertensive properties that has been used for the control of high blood pressure and for the relief of psychotic behavior. | Nitrous acid (as sodium nitrite) is used as part of an intravenous mixture with sodium thiosulfate to treat cyanide poisoning. It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system. There is also research to investigate its applica... | Moderate | 1 | [
[
[
1340,
24,
1455
]
],
[
[
1340,
1,
1245
],
[
1245,
24,
1455
]
],
[
[
1340,
24,
1450
],
[
1450,
24,
1455
]
],
[
[
1340,
63,
714
],
[
714,... | [
[
[
"Deserpidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
]
],
[
[
"Deserpidine",
"{u} (Compound) resembles {v} (Compound)",
"Reserpine"
],
[
"Reserpine",
"{u} may cause a moder... | Deserpidine (Compound) resembles Reserpine (Compound) and Reserpine may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid
Deserpidine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction th... |
DB00214 | DB11057 | 1,028 | 720 | [
"DDInter1836",
"DDInter1223"
] | Torasemide | Mineral oil | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
1028,
24,
720
]
],
[
[
1028,
24,
175
],
[
175,
24,
720
]
],
[
[
1028,
25,
1425
],
[
1425,
24,
720
]
],
[
[
1028,
63,
600
],
[
600,
... | [
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
... | Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Torasemide may lead to a major life threatening interaction when taken with Cisapride and Cisapride may c... |
DB00497 | DB06674 | 828 | 908 | [
"DDInter1366",
"DDInter837"
] | Oxycodone | Golimumab | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Moderate | 1 | [
[
[
828,
24,
908
]
],
[
[
828,
24,
522
],
[
522,
24,
908
]
],
[
[
828,
25,
1593
],
[
1593,
63,
908
]
],
[
[
828,
63,
58
],
[
58,
24,... | [
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
],
[
... | Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Oxycodone may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a... |
DB00640 | DB08871 | 1,585 | 36 | [
"DDInter31",
"DDInter666"
] | Adenosine | Eribulin | The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by [dipyridamole]... | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Moderate | 1 | [
[
[
1585,
24,
36
]
],
[
[
1585,
1,
1488
],
[
1488,
24,
36
]
],
[
[
1585,
64,
1424
],
[
1424,
24,
36
]
],
[
[
1585,
24,
820
],
[
820,
... | [
[
[
"Adenosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Adenosine",
"{u} (Compound) resembles {v} (Compound)",
"Fludarabine"
],
[
"Fludarabine",
"{u} may cause a moderate ... | Adenosine (Compound) resembles Fludarabine (Compound) and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Adenosine may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases wh... |
DB00013 | DB00722 | 1,255 | 743 | [
"DDInter1905",
"DDInter1079"
] | Urokinase | Lisinopril | Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978. | Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldos... | Moderate | 1 | [
[
[
1255,
24,
743
]
],
[
[
1255,
24,
610
],
[
610,
40,
743
]
],
[
[
1255,
24,
1638
],
[
1638,
1,
743
]
],
[
[
1255,
25,
500
],
[
500,
... | [
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisinopril"
]
],
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enalapril"
],
[
... | Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Enalapril and Enalapril (Compound) resembles Lisinopril (Compound)
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Lisinopril (Compound)
... |
DB08903 | DB14568 | 996 | 982 | [
"DDInter170",
"DDInter1000"
] | Bedaquiline | Ivosidenib | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Major | 2 | [
[
[
996,
25,
982
]
],
[
[
996,
62,
112
],
[
112,
23,
982
]
],
[
[
996,
63,
168
],
[
168,
23,
982
]
],
[
[
996,
63,
543
],
[
543,
24,... | [
[
[
"Bedaquiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Bedaquiline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metroni... | Bedaquiline may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Bedaquiline may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bo... |
DB00218 | DB00414 | 1,176 | 590 | [
"DDInter1247",
"DDInter16"
] | Moxifloxacin | Acetohexamide | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Major | 2 | [
[
[
1176,
25,
590
]
],
[
[
1176,
24,
1475
],
[
1475,
62,
590
]
],
[
[
1176,
24,
848
],
[
848,
63,
590
]
],
[
[
1176,
25,
1424
],
[
1424,
... | [
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acetohexamide"
]
],
[
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium citrate"
],
[
... | Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Sodium citrate and Sodium citrate may cause a minor interaction that can limit clinical effects when taken with Acetohexamide
Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofe... |
DB00880 | DB01124 | 359 | 1,411 | [
"DDInter360",
"DDInter1828"
] | Chlorothiazide | Tolbutamide | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812) | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
359,
24,
1411
]
],
[
[
359,
24,
959
],
[
959,
40,
1411
]
],
[
[
359,
63,
245
],
[
245,
40,
1411
]
],
[
[
359,
6,
10612
],
[
10612,
... | [
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
... | Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (... |
DB01225 | DB10897 | 500 | 539 | [
"DDInter645",
"DDInter291"
] | Enoxaparin | Capsicum | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the inc... | Capsicum (Chili pepper) allergenic extract is used in allergenic testing. | Minor | 0 | [
[
[
500,
23,
539
]
],
[
[
500,
25,
885
],
[
885,
23,
539
]
],
[
[
500,
64,
702
],
[
702,
23,
539
]
],
[
[
500,
25,
1421
],
[
1421,
6... | [
[
[
"Enoxaparin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
]
],
[
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol... | Enoxaparin may lead to a major life threatening interaction when taken with Epoprostenol and Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Capsicum
Enoxaparin may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may cause a minor interac... |
DB11901 | DB12332 | 913 | 1,619 | [
"DDInter107",
"DDInter1626"
] | Apalutamide | Rucaparib | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements. It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resi... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
913,
24,
1619
]
],
[
[
913,
62,
271
],
[
271,
23,
1619
]
],
[
[
913,
64,
1135
],
[
1135,
23,
1619
]
],
[
[
913,
25,
907
],
[
907,
... | [
[
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Apalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
],
[
... | Apalutamide may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Apalutamide may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a min... |
DB00106 | DB01175 | 618 | 318 | [
"DDInter4",
"DDInter672"
] | Abarelix | Escitalopram | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Major | 2 | [
[
[
618,
25,
318
]
],
[
[
618,
25,
1230
],
[
1230,
1,
318
]
],
[
[
618,
24,
384
],
[
384,
62,
318
]
],
[
[
618,
23,
112
],
[
112,
23... | [
[
[
"Abarelix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Escitalopram"
]
],
[
[
"Abarelix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Citalopram"
],
[
"Citalopram",
"{u} (Co... | Abarelix may lead to a major life threatening interaction when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a minor interaction that can limit clinical effect... |
DB01193 | DB04843 | 819 | 1,511 | [
"DDInter12",
"DDInter1149"
] | Acebutolol | Mepenzolate | A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Moderate | 1 | [
[
[
819,
24,
1511
]
],
[
[
819,
63,
1192
],
[
1192,
24,
1511
]
],
[
[
819,
21,
28898
],
[
28898,
60,
1511
]
],
[
[
819,
24,
849
],
[
849,
... | [
[
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
],
... | Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium and Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Acebutolol (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Mep... |
DB00519 | DB09268 | 1,638 | 1,662 | [
"DDInter1843",
"DDInter1464"
] | Trandolapril | Picosulfuric acid | Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiote... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
1638,
24,
1662
]
],
[
[
1638,
24,
708
],
[
708,
24,
1662
]
],
[
[
1638,
63,
912
],
[
912,
24,
1662
]
],
[
[
1638,
24,
407
],
[
407,
... | [
[
[
"Trandolapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Trandolapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
... | Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Inte... |
DB00397 | DB01381 | 1,466 | 958 | [
"DDInter1458",
"DDInter819"
] | Phenylpropanolamine | Ginkgo biloba | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | _Ginkgo biloba_ extract contains a group of terpene lactones (notably, ginkgolides and diterpenes) and ginkgo flavone glycosides (notably, ginkgetin, bilobetin, and sciadopitysin) that have antioxidant and vasoactive properties. Most of the studies that investigate the effect of _ginkgo biloba_ use the standardized ext... | Moderate | 1 | [
[
[
1466,
24,
958
]
],
[
[
1466,
64,
73
],
[
73,
24,
958
]
],
[
[
1466,
25,
121
],
[
121,
24,
958
]
],
[
[
1466,
24,
714
],
[
714,
2... | [
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginkgo biloba"
]
],
[
[
"Phenylpropanolamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phentermine"
],
... | Phenylpropanolamine may lead to a major life threatening interaction when taken with Phentermine and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Ginkgo biloba
Phenylpropanolamine may lead to a major life threatening interaction when taken with Fenfluramine and Fenfluramin... |
DB00497 | DB00748 | 828 | 662 | [
"DDInter1366",
"DDInter297"
] | Oxycodone | Carbinoxamine | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Moderate | 1 | [
[
[
828,
24,
662
]
],
[
[
828,
63,
1594
],
[
1594,
24,
662
]
],
[
[
828,
6,
8374
],
[
8374,
45,
662
]
],
[
[
828,
21,
28921
],
[
28921,
... | [
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Oxycodone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Carbinoxamine (Compound)
Oxycodone (Com... |
DB00041 | DB00598 | 1,648 | 1,523 | [
"DDInter38",
"DDInter1013"
] | Aldesleukin | Labetalol | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Moderate | 1 | [
[
[
1648,
24,
1523
]
],
[
[
1648,
24,
954
],
[
954,
1,
1523
]
],
[
[
1648,
24,
482
],
[
482,
24,
1523
]
],
[
[
1648,
25,
497
],
[
497,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
],
[
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril (Compound) resembles Labetalol (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could ... |
DB00395 | DB01246 | 210 | 820 | [
"DDInter301",
"DDInter45"
] | Carisoprodol | Alimemazine | Originally approved by the FDA in 1959 [FDA label], carisoprodol is a centrally acting muscle relaxant used in painful musculoskeletal conditions in conjunction with physical therapy and other medications. This drug is available by itself in an oral tablet or combined with aspirin, or in a fixed-dose combination with b... | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
210,
24,
820
]
],
[
[
210,
24,
104
],
[
104,
40,
820
]
],
[
[
210,
24,
401
],
[
401,
24,
820
]
],
[
[
210,
24,
649
],
[
649,
1,
... | [
[
[
"Carisoprodol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Carisoprodol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
... | Carisoprodol may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Carisoprodol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interacti... |
DB00495 | DB09570 | 139 | 1,480 | [
"DDInter1961",
"DDInter1002"
] | Zidovudine | Ixazomib | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain... | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Moderate | 1 | [
[
[
139,
24,
1480
]
],
[
[
139,
64,
268
],
[
268,
24,
1480
]
],
[
[
139,
63,
66
],
[
66,
24,
1480
]
],
[
[
139,
24,
310
],
[
310,
24... | [
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Zidovudine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Peginterferon alfa-2b"
],
[
"P... | Zidovudine may lead to a major life threatening interaction when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and E... |
DB00218 | DB00682 | 1,176 | 126 | [
"DDInter1247",
"DDInter1951"
] | Moxifloxacin | Warfarin | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Major | 2 | [
[
[
1176,
25,
126
]
],
[
[
1176,
24,
135
],
[
135,
62,
126
]
],
[
[
1176,
23,
1001
],
[
1001,
62,
126
]
],
[
[
1176,
24,
663
],
[
663,
... | [
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
]
],
[
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
],
[
"Albiglu... | Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide and Albiglutide may cause a minor interaction that can limit clinical effects when taken with Warfarin
Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Mechlorethamine and M... |
DB00069 | DB06317 | 367 | 1,626 | [
"DDInter946",
"DDInter630"
] | Interferon alfacon-1 | Elotuzumab | Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional am... | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family... | Moderate | 1 | [
[
[
367,
24,
1626
]
],
[
[
367,
24,
973
],
[
973,
24,
1626
]
],
[
[
367,
24,
310
],
[
310,
63,
1626
]
],
[
[
367,
63,
912
],
[
912,
... | [
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclita... | Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with C... |
DB00295 | DB00985 | 475 | 1,443 | [
"DDInter1244",
"DDInter562"
] | Morphine | Dimenhydrinate | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Dimehydrinate was first described in the literature in 1949, and patented in 1950. Early research into dimenhydrinate focused on its role as an antihistamine for urticaria; the treatment of motion sickness was an accidental discovery. Dimenhydrinate, also known as B-dimethylaminoethyl benzohydrol ether 8-chlorotheophyl... | Moderate | 1 | [
[
[
475,
24,
1443
]
],
[
[
475,
24,
1376
],
[
1376,
63,
1443
]
],
[
[
475,
63,
357
],
[
357,
1,
1443
]
],
[
[
475,
25,
358
],
[
358,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimenhydrinate"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
... | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Dimenhydrinate
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Benzatropin... |
DB01589 | DB11130 | 481 | 407 | [
"DDInter1552",
"DDInter1344"
] | Quazepam | Opium | Quazepam is a trifluoroethyl benzodiazepine derivative. It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors a... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
481,
24,
407
]
],
[
[
481,
63,
662
],
[
662,
24,
407
]
],
[
[
481,
24,
849
],
[
849,
24,
407
]
],
[
[
481,
40,
1563
],
[
1563,
2... | [
[
[
"Quazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Quazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"C... | Quazepam may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Quazepam may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramin... |
DB00515 | DB11003 | 589 | 748 | [
"DDInter387",
"DDInter100"
] | Cisplatin | Anthrax vaccine | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Moderate | 1 | [
[
[
589,
24,
748
]
],
[
[
589,
63,
322
],
[
322,
24,
748
]
],
[
[
589,
24,
896
],
[
896,
24,
748
]
],
[
[
589,
25,
676
],
[
676,
63,... | [
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[... | Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etop... |
DB09075 | DB09293 | 498 | 116 | [
"DDInter621",
"DDInter954"
] | Edoxaban | Iodide I-131 | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Iodine-131 is notable for causing mutation and death in cells that it penetrates, which is due to its mode of beta decay. As a result of beta decay, approximately 10% of its energy and radiation do... | Moderate | 1 | [
[
[
498,
24,
116
]
],
[
[
498,
24,
1004
],
[
1004,
63,
116
]
],
[
[
498,
64,
365
],
[
365,
24,
116
]
],
[
[
498,
25,
18
],
[
18,
63,... | [
[
[
"Edoxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Edoxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyl salicylate"
],
... | Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate and Phenyl salicylate may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Edoxaban may lead to a major life threatening interaction when taken with Dalteparin and Daltepari... |
DB01324 | DB09104 | 178 | 286 | [
"DDInter1490",
"DDInter1118"
] | Polythiazide | Magnesium hydroxide | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
178,
24,
286
]
],
[
[
178,
63,
820
],
[
820,
23,
286
]
],
[
[
178,
63,
688
],
[
688,
24,
286
]
],
[
[
178,
62,
1669
],
[
1669,
2... | [
[
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
... | Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Salbutam... |
DB00176 | DB00455 | 529 | 1,601 | [
"DDInter770",
"DDInter1091"
] | Fluvoxamine | Loratadine | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Loratadine is a second generation antihistamine used to manage symptoms of allergic rhinitis. A lack of sedative and CNS adverse effects make loratadine, along with other second generation antihistamines, preferable over their 1st generation counterparts in many clinical situations. | Moderate | 1 | [
[
[
529,
24,
1601
]
],
[
[
529,
24,
1219
],
[
1219,
1,
1601
]
],
[
[
529,
6,
8374
],
[
8374,
45,
1601
]
],
[
[
529,
18,
16974
],
[
16974,
... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loratadine"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
],
[
... | Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine and Azatadine (Compound) resembles Loratadine (Compound)
Fluvoxamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Loratadine (Compound)
Fluvoxamine (Compound) downregulates TUBB6 (Gene) and TUBB6 (Gene)... |
DB05015 | DB10989 | 1,077 | 496 | [
"DDInter174",
"DDInter858"
] | Belinostat | Hepatitis A Vaccine | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with... | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infectio... | Moderate | 1 | [
[
[
1077,
24,
496
]
],
[
[
1077,
63,
4
],
[
4,
24,
496
]
],
[
[
1077,
24,
850
],
[
850,
24,
496
]
],
[
[
1077,
24,
738
],
[
738,
63,... | [
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesu... | Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Belinostat may cause a moderate interaction that could exacerbate disease... |
DB00662 | DB01202 | 717 | 1,435 | [
"DDInter1873",
"DDInter1046"
] | Trimethobenzamide | Levetiracetam | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs).[L8606,L8600,L8615] Levetiracetam poss... | Moderate | 1 | [
[
[
717,
24,
1435
]
],
[
[
717,
21,
28921
],
[
28921,
60,
1435
]
],
[
[
717,
63,
701
],
[
701,
24,
1435
]
],
[
[
717,
24,
1219
],
[
1219,
... | [
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levetiracetam"
]
],
[
[
"Trimethobenzamide",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Sid... | Trimethobenzamide (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Levetiracetam (Compound)
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when t... |
DB00224 | DB01083 | 215 | 1,142 | [
"DDInter917",
"DDInter1348"
] | Indinavir | Orlistat | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical inter... | Moderate | 1 | [
[
[
215,
24,
1142
]
],
[
[
215,
6,
8374
],
[
8374,
45,
1142
]
],
[
[
215,
21,
28645
],
[
28645,
60,
1142
]
],
[
[
215,
24,
5
],
[
5,
... | [
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orlistat"
]
],
[
[
"Indinavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Indinavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Orlistat (Compound)
Indinavir (Compound) causes Cough (Side Effect) and Cough (Side Effect) is caused by Orlistat (Compound)
Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide and Liraglutide may ca... |
DB00421 | DB09472 | 443 | 1,383 | [
"DDInter1707",
"DDInter1693"
] | Spironolactone | Sodium sulfate | Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were disco... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
443,
24,
1383
]
],
[
[
443,
24,
1342
],
[
1342,
24,
1383
]
],
[
[
443,
24,
971
],
[
971,
63,
1383
]
],
[
[
443,
25,
1250
],
[
1250,
... | [
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
... | Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Gilteriti... |
DB00443 | DB01265 | 251 | 1,477 | [
"DDInter195",
"DDInter1757"
] | Betamethasone | Telbivudine | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Telbivudine is a synthetic thymidine nucleoside analog with specific activity against the hepatitis B virus. Telbivudine is orally administered, with good tolerance, lack of toxicity and no dose-limiting side effects. | Moderate | 1 | [
[
[
251,
24,
1477
]
],
[
[
251,
24,
139
],
[
139,
1,
1477
]
],
[
[
251,
21,
28745
],
[
28745,
60,
1477
]
],
[
[
251,
1,
1220
],
[
1220,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telbivudine"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
],
... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine (Compound) resembles Telbivudine (Compound)
Betamethasone (Compound) causes Neuropathy peripheral (Side Effect) and Neuropathy peripheral (Side Effect) is caused by Telbivudine (Compound)
Betamethason... |
DB00424 | DB04843 | 19 | 1,511 | [
"DDInter896",
"DDInter1149"
] | Hyoscyamine | Mepenzolate | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimus... | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Moderate | 1 | [
[
[
19,
24,
1511
]
],
[
[
19,
24,
675
],
[
675,
24,
1511
]
],
[
[
19,
63,
352
],
[
352,
24,
1511
]
],
[
[
19,
74,
357
],
[
357,
24,
... | [
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextropropoxyphene"
... | Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Tr... |
DB06616 | DB06699 | 594 | 774 | [
"DDInter224",
"DDInter493"
] | Bosutinib | Degarelix | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Moderate | 1 | [
[
[
594,
24,
774
]
],
[
[
594,
63,
521
],
[
521,
1,
774
]
],
[
[
594,
21,
29232
],
[
29232,
60,
774
]
],
[
[
594,
62,
112
],
[
112,
... | [
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
... | Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Bosutinib (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Degarelix (Compound)
Bosutinib may cause a minor interaction that can l... |
DB01175 | DB05812 | 318 | 1,374 | [
"DDInter672",
"DDInter8"
] | Escitalopram | Abiraterone | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Major | 2 | [
[
[
318,
25,
1374
]
],
[
[
318,
6,
12523
],
[
12523,
45,
1374
]
],
[
[
318,
21,
29113
],
[
29113,
60,
1374
]
],
[
[
318,
62,
112
],
[
112,... | [
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abiraterone"
]
],
[
[
"Escitalopram",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Ab... | Escitalopram (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Abiraterone (Compound)
Escitalopram (Compound) causes Hypokalaemia (Side Effect) and Hypokalaemia (Side Effect) is caused by Abiraterone (Compound)
Escitalopram may cause a minor interaction that can limit clinical effects when taken with Metroni... |
DB01050 | DB01067 | 848 | 959 | [
"DDInter900",
"DDInter826"
] | Ibuprofen | Glipizide | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
848,
24,
959
]
],
[
[
848,
63,
245
],
[
245,
40,
959
]
],
[
[
848,
24,
1411
],
[
1411,
1,
959
]
],
[
[
848,
6,
4789
],
[
4789,
4... | [
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
... | Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compound)
... |
DB04855 | DB06699 | 540 | 774 | [
"DDInter602",
"DDInter493"
] | Dronedarone | Degarelix | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate contro... | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Major | 2 | [
[
[
540,
25,
774
]
],
[
[
540,
64,
521
],
[
521,
1,
774
]
],
[
[
540,
21,
28703
],
[
28703,
60,
774
]
],
[
[
540,
62,
112
],
[
112,
... | [
[
[
"Dronedarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Degarelix"
]
],
[
[
"Dronedarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} (C... | Dronedarone may lead to a major life threatening interaction when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Dronedarone (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Degarelix (Compound)
Dronedarone may cause a minor interaction that can limit clinic... |
DB00427 | DB09420 | 1,233 | 1,074 | [
"DDInter1879",
"DDInter953"
] | Triprolidine | Iodide I-123 | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect t... | Moderate | 1 | [
[
[
1233,
24,
1074
]
],
[
[
1233,
24,
516
],
[
516,
24,
1074
]
],
[
[
1233,
63,
902
],
[
902,
24,
1074
]
],
[
[
1233,
24,
1399
],
[
1399,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Clobaza... |
DB06717 | DB09074 | 875 | 1,362 | [
"DDInter778",
"DDInter1327"
] | Fosaprepitant | Olaparib | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Major | 2 | [
[
[
875,
25,
1362
]
],
[
[
875,
63,
896
],
[
896,
24,
1362
]
],
[
[
875,
25,
1478
],
[
1478,
24,
1362
]
],
[
[
875,
24,
1619
],
[
1619,
... | [
[
[
"Fosaprepitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
],
[
[
"Fosaprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
"Etoposi... | Fosaprepitant may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Fosaprepitant may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause ... |
DB00465 | DB04932 | 886 | 1,564 | [
"DDInter1010",
"DDInter491"
] | Ketorolac | Defibrotide | Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, men... | Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects). It is marketed under the brand names Da... | Moderate | 1 | [
[
[
886,
24,
1564
]
],
[
[
886,
24,
1039
],
[
1039,
24,
1564
]
],
[
[
886,
24,
738
],
[
738,
63,
1564
]
],
[
[
886,
25,
1512
],
[
1512,
... | [
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Defibrotide"
]
],
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
],
... | Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Defibrotide
Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Niraparib an... |
DB08904 | DB12893 | 375 | 586 | [
"DDInter342",
"DDInter1629"
] | Certolizumab pegol | Sacituzumab govitecan | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Metastatic triple-negative breast cancer (mTNBC) is an aggressive form of breast cancer with limited treatment options involving cytotoxic chemotherapy agents. Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment. One such ADC is sacituzumab goviteca... | Major | 2 | [
[
[
375,
25,
586
]
],
[
[
375,
25,
270
],
[
270,
24,
586
]
],
[
[
375,
63,
58
],
[
58,
24,
586
]
],
[
[
375,
64,
1184
],
[
1184,
24,... | [
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sacituzumab govitecan"
]
],
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
],
[
... | Certolizumab pegol may lead to a major life threatening interaction when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Sacituzumab govitecan
Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Aleface... |
DB01229 | DB06595 | 973 | 1,491 | [
"DDInter1377",
"DDInter1214"
] | Paclitaxel | Midostaurin | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
973,
24,
1491
]
],
[
[
973,
63,
112
],
[
112,
23,
1491
]
],
[
[
973,
63,
289
],
[
289,
24,
1491
]
],
[
[
973,
24,
1017
],
[
1017,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cerivastatin and... |
DB00682 | DB09301 | 126 | 1,034 | [
"DDInter1951",
"DDInter371"
] | Warfarin | Chondroitin sulfate | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Chondroitin sulfate is a glycosaminoglycan considered as a symptomatic slow-acting drug for osteoarthritis (SYSADOA). The SYSADOA status suggested a pain relief and increased joint mobility after a relative long regular administration, as well as a long-lasting effect after the end of the treatment. Chondroitin sulfate... | Moderate | 1 | [
[
[
126,
24,
1034
]
]
] | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chondroitin sulfate"
]
]
] | |
DB01259 | DB06176 | 392 | 1,342 | [
"DDInter1024",
"DDInter1616"
] | Lapatinib | Romidepsin | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
392,
24,
1342
]
],
[
[
392,
62,
1247
],
[
1247,
23,
1342
]
],
[
[
392,
63,
336
],
[
336,
24,
1342
]
],
[
[
392,
24,
1616
],
[
1616,
... | [
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Lapatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
... | Lapatinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and ... |
DB00342 | DB12267 | 1,181 | 1,476 | [
"DDInter1770",
"DDInter233"
] | Terfenadine | Brigatinib | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
1181,
24,
1476
]
],
[
[
1181,
24,
1612
],
[
1612,
23,
1476
]
],
[
[
1181,
24,
629
],
[
629,
24,
1476
]
],
[
[
1181,
25,
918
],
[
918,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[... | Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirol... |
DB00282 | DB01249 | 641 | 258 | [
"DDInter1383",
"DDInter958"
] | Pamidronic acid | Iodixanol | Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to [neridronic acid] and [alendronic acid]. Pamidronic acid was first described in the literature in 1977. The second generation bisphosphonates are less common as third generation bisphosphonates, such as [ibandronic acid], [zoledronic ... | Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents. | Major | 2 | [
[
[
641,
25,
258
]
],
[
[
641,
25,
497
],
[
497,
1,
258
]
],
[
[
641,
21,
28757
],
[
28757,
60,
258
]
],
[
[
641,
24,
712
],
[
712,
... | [
[
[
"Pamidronic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iodixanol"
]
],
[
[
"Pamidronic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u... | Pamidronic acid may lead to a major life threatening interaction when taken with Iohexol and Iohexol (Compound) resembles Iodixanol (Compound)
Pamidronic acid (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Iodixanol (Compound)
Pamidronic acid may cause a moderate interaction that cou... |
DB01294 | DB08816 | 266 | 578 | [
"DDInter215",
"DDInter1802"
] | Bismuth subsalicylate | Ticagrelor | Bismuth subsalicylate is an antacid and anti-diarrheal agent. Exhibiting antibacterial and gastroprotective properties, bismuth subsalicylate is an insoluble salt of [salicylic acid] linked to trivalent [bismuth cation]. Each molecule of bismuth subsalicylate contains 58% bismuth and 42% salicylate by weight. Bismuth s... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
266,
24,
578
]
],
[
[
266,
21,
28762
],
[
28762,
60,
578
]
],
[
[
266,
63,
1578
],
[
1578,
24,
578
]
],
[
[
266,
24,
235
],
[
235,
... | [
[
[
"Bismuth subsalicylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Bismuth subsalicylate",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (... | Bismuth subsalicylate (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ticagrelor (Compound)
Bismuth subsalicylate may cause a moderate interaction that could exacerbate diseases when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when ... |
DB00661 | DB00712 | 122 | 1,274 | [
"DDInter1928",
"DDInter763"
] | Verapamil | Flurbiprofen | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Moderate | 1 | [
[
[
122,
24,
1274
]
],
[
[
122,
6,
9320
],
[
9320,
45,
1274
]
],
[
[
122,
21,
28769
],
[
28769,
60,
1274
]
],
[
[
122,
63,
752
],
[
752,
... | [
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
]
],
[
[
"Verapamil",
"{u} (Compound) binds {v} (Gene)",
"ABCC4"
],
[
"ABCC4",
"{u} (Gene) is bound by {v} (Compound)",
... | Verapamil (Compound) binds ABCC4 (Gene) and ABCC4 (Gene) is bound by Flurbiprofen (Compound)
Verapamil (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Flurbiprofen (Compound)
Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Cimeti... |
DB00559 | DB00916 | 152 | 112 | [
"DDInter223",
"DDInter1202"
] | Bosentan | Metronidazole | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Moderate | 1 | [
[
[
152,
24,
112
]
],
[
[
152,
6,
8374
],
[
8374,
45,
112
]
],
[
[
152,
21,
28692
],
[
28692,
60,
112
]
],
[
[
152,
63,
752
],
[
752,
... | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
]
],
[
[
"Bosentan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Bosentan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Metronidazole (Compound)
Bosentan (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Metronidazole (Compound)
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Cimetid... |
DB01155 | DB12245 | 872 | 823 | [
"DDInter813",
"DDInter1863"
] | Gemifloxacin | Triclabendazole | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase... | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Moderate | 1 | [
[
[
872,
24,
823
]
],
[
[
872,
62,
112
],
[
112,
23,
823
]
],
[
[
872,
63,
1010
],
[
1010,
24,
823
]
],
[
[
872,
24,
28
],
[
28,
24,... | [
[
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Gemifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
]... | Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine... |
DB08903 | DB09078 | 996 | 1,228 | [
"DDInter170",
"DDInter1036"
] | Bedaquiline | Lenvatinib | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Major | 2 | [
[
[
996,
25,
1228
]
],
[
[
996,
62,
112
],
[
112,
23,
1228
]
],
[
[
996,
64,
609
],
[
609,
24,
1228
]
],
[
[
996,
63,
770
],
[
770,
... | [
[
[
"Bedaquiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
]
],
[
[
"Bedaquiline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metroni... | Bedaquiline may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Bedaquiline may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromyci... |
DB00649 | DB01098 | 231 | 14 | [
"DDInter1710",
"DDInter1622"
] | Stavudine | Rosuvastatin | A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Moderate | 1 | [
[
[
231,
24,
14
]
],
[
[
231,
21,
29462
],
[
29462,
60,
14
]
],
[
[
231,
63,
305
],
[
305,
24,
14
]
],
[
[
231,
24,
1487
],
[
1487,
... | [
[
[
"Stavudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Stavudine",
"{u} (Compound) causes {v} (Side Effect)",
"Influenza"
],
[
"Influenza",
"{u} (Side Effect) is caus... | Stavudine (Compound) causes Influenza (Side Effect) and Influenza (Side Effect) is caused by Rosuvastatin (Compound)
Stavudine may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exace... |
DB00500 | DB00795 | 24 | 50 | [
"DDInter1831",
"DDInter1725"
] | Tolmetin | Sulfasalazine | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down i... | Moderate | 1 | [
[
[
24,
24,
50
]
],
[
[
24,
24,
712
],
[
712,
1,
50
]
],
[
[
24,
10,
11591
],
[
11591,
44,
50
]
],
[
[
24,
6,
10522
],
[
10522,
45,
... | [
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
]
],
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olsalazine"
],
[
... | Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine (Compound) resembles Sulfasalazine (Compound)
Tolmetin (Compound) palliates ankylosing spondylitis (Disease) and ankylosing spondylitis (Disease) is treated by Sulfasalazine (Compound)
Tolmetin (Compound) ... |
DB00468 | DB12825 | 1,424 | 1,375 | [
"DDInter1557",
"DDInter1032"
] | Quinine | Lefamulin | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Major | 2 | [
[
[
1424,
25,
1375
]
],
[
[
1424,
23,
112
],
[
112,
23,
1375
]
],
[
[
1424,
24,
159
],
[
159,
63,
1375
]
],
[
[
1424,
63,
1101
],
[
1101,
... | [
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
]
],
[
[
"Quinine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
... | Quinine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lefamulin
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrec... |
DB00722 | DB01069 | 743 | 401 | [
"DDInter1079",
"DDInter1533"
] | Lisinopril | Promethazine | Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldos... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
743,
24,
401
]
],
[
[
743,
24,
1264
],
[
1264,
63,
401
]
],
[
[
743,
24,
104
],
[
104,
24,
401
]
],
[
[
743,
6,
4973
],
[
4973,
... | [
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdila... |
DB00813 | DB12332 | 704 | 1,619 | [
"DDInter722",
"DDInter1626"
] | Fentanyl | Rucaparib | Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
704,
24,
1619
]
],
[
[
704,
25,
222
],
[
222,
23,
1619
]
],
[
[
704,
40,
307
],
[
307,
23,
1619
]
],
[
[
704,
24,
259
],
[
259,
... | [
[
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Fentanyl",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
... | Fentanyl may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Fentanyl (Compound) resembles Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects whe... |
DB01138 | DB09143 | 804 | 313 | [
"DDInter1726",
"DDInter1701"
] | Sulfinpyrazone | Sonidegib | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Moderate | 1 | [
[
[
804,
24,
313
]
],
[
[
804,
24,
478
],
[
478,
24,
313
]
],
[
[
804,
24,
484
],
[
484,
63,
313
]
],
[
[
804,
25,
1213
],
[
1213,
2... | [
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sonidegib"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
... | Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Sonidegib
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and ... |
DB00694 | DB06212 | 51 | 165 | [
"DDInter485",
"DDInter1833"
] | Daunorubicin | Tolvaptan | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009. | Moderate | 1 | [
[
[
51,
24,
165
]
],
[
[
51,
24,
1080
],
[
1080,
1,
165
]
],
[
[
51,
6,
8374
],
[
8374,
45,
165
]
],
[
[
51,
21,
28981
],
[
28981,
6... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolvaptan"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conivaptan"
],
[... | Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Conivaptan and Conivaptan (Compound) resembles Tolvaptan (Compound)
Daunorubicin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tolvaptan (Compound)
Daunorubicin (Compound) causes Renal impairment (Side Effect) an... |
DB00397 | DB00723 | 1,466 | 1,240 | [
"DDInter1458",
"DDInter1176"
] | Phenylpropanolamine | Methoxamine | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | An alpha-adrenergic agonist that causes prolonged peripheral vasoconstriction. It has little if any direct effect on the central nervous system. | Moderate | 1 | [
[
[
1466,
24,
1240
]
],
[
[
1466,
63,
1290
],
[
1290,
40,
1240
]
],
[
[
1466,
35,
584
],
[
584,
40,
1240
]
],
[
[
1466,
1,
1357
],
[
1357,... | [
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methoxamine"
]
],
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midodrin... | Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Midodrine and Midodrine (Compound) resembles Methoxamine (Compound)
Phenylpropanolamine (Compound) resembles Levonordefrin (Compound) and Phenylpropanolamine may cause a moderate interaction that could exacerbate disease... |
DB00603 | DB08881 | 303 | 868 | [
"DDInter1137",
"DDInter1925"
] | Medroxyprogesterone acetate | Vemurafenib | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
303,
24,
868
]
],
[
[
303,
6,
8374
],
[
8374,
45,
868
]
],
[
[
303,
18,
8386
],
[
8386,
46,
868
]
],
[
[
303,
7,
8924
],
[
8924,
... | [
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} ... | Medroxyprogesterone acetate (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Medroxyprogesterone acetate (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Vemurafenib (Compound)
Medroxyprogesterone acetate (Compound) upregulates SPAG4 (Gene) and SPAG4 (Gene) i... |
DB00278 | DB08816 | 291 | 578 | [
"DDInter117",
"DDInter1802"
] | Argatroban | Ticagrelor | Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant sh... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
291,
24,
578
]
],
[
[
291,
6,
8374
],
[
8374,
45,
578
]
],
[
[
291,
21,
28645
],
[
28645,
60,
578
]
],
[
[
291,
23,
297
],
[
297,
... | [
[
[
"Argatroban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Argatroban",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Argatroban (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ticagrelor (Compound)
Argatroban (Compound) causes Cough (Side Effect) and Cough (Side Effect) is caused by Ticagrelor (Compound)
Argatroban may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a m... |
DB01097 | DB06643 | 1,377 | 1,136 | [
"DDInter1033",
"DDInter500"
] | Leflunomide | Denosumab | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Moderate | 1 | [
[
[
1377,
24,
1136
]
],
[
[
1377,
25,
1213
],
[
1213,
24,
1136
]
],
[
[
1377,
64,
1555
],
[
1555,
24,
1136
]
],
[
[
1377,
25,
1316
],
[
13... | [
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib"... | Leflunomide may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Leflunomide may lead to a major life threatening interaction when taken with Oxaliplatin and Oxaliplatin may cause a moderate int... |
DB06176 | DB11730 | 1,342 | 351 | [
"DDInter1616",
"DDInter1588"
] | Romidepsin | Ribociclib | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
1342,
25,
351
]
],
[
[
1342,
62,
1247
],
[
1247,
23,
351
]
],
[
[
1342,
24,
283
],
[
283,
62,
351
]
],
[
[
1342,
63,
479
],
[
479,
... | [
[
[
"Romidepsin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Romidepsin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfam... | Romidepsin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib an... |
DB00366 | DB00844 | 1,594 | 314 | [
"DDInter600",
"DDInter1257"
] | Doxylamine | Nalbuphine | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States. | Moderate | 1 | [
[
[
1594,
24,
314
]
],
[
[
1594,
24,
828
],
[
828,
40,
314
]
],
[
[
1594,
63,
421
],
[
421,
1,
314
]
],
[
[
1594,
63,
475
],
[
475,
... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalbuphine"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
],
[
... | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone (Compound) resembles Nalbuphine (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Nalbuphine (Compou... |
DB00668 | DB01168 | 874 | 1,053 | [
"DDInter652",
"DDInter1526"
] | Epinephrine | Procarbazine | Epinephrine, also known as _adrenaline_, is a hormone and neurotransmitter and produced by the adrenal glands that can also be used as a drug due to its various important functions. Though it has long been used in the treatment of hypersensitivity reactions, epinephrine in the auto-injector form (EpiPen) has been avail... | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Moderate | 1 | [
[
[
874,
24,
1053
]
],
[
[
874,
21,
29024
],
[
29024,
60,
1053
]
],
[
[
874,
63,
1000
],
[
1000,
24,
1053
]
],
[
[
874,
24,
480
],
[
480,
... | [
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Epinephrine",
"{u} (Compound) causes {v} (Side Effect)",
"Hypertension"
],
[
"Hypertension",
"{u} (Side Effec... | Epinephrine (Compound) causes Hypertension (Side Effect) and Hypertension (Side Effect) is caused by Procarbazine (Compound)
Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Guanadrel and Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with... |
DB01045 | DB05812 | 463 | 1,374 | [
"DDInter1590",
"DDInter8"
] | Rifampicin | Abiraterone | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Major | 2 | [
[
[
463,
25,
1374
]
],
[
[
463,
6,
10417
],
[
10417,
45,
1374
]
],
[
[
463,
25,
466
],
[
466,
62,
1374
]
],
[
[
463,
63,
112
],
[
112,
... | [
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abiraterone"
]
],
[
[
"Rifampicin",
"{u} (Compound) binds {v} (Gene)",
"ABCC1"
],
[
"ABCC1",
"{u} (Gene) is bound by {v} (Compound)",
"Abirater... | Rifampicin (Compound) binds ABCC1 (Gene) and ABCC1 (Gene) is bound by Abiraterone (Compound)
Rifampicin may lead to a major life threatening interaction when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Abiraterone
Rifampicin may cause a moderate... |
DB00163 | DB00758 | 1,461 | 1,347 | [
"DDInter1943",
"DDInter413"
] | Vitamin E | Clopidogrel | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are ... | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Moderate | 1 | [
[
[
1461,
24,
1347
]
],
[
[
1461,
24,
1018
],
[
1018,
25,
1347
]
],
[
[
1461,
18,
16229
],
[
16229,
46,
1347
]
],
[
[
1461,
24,
578
],
[
5... | [
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
... | Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may lead to a major life threatening interaction when taken with Clopidogrel
Vitamin E (Compound) downregulates SPRED2 (Gene) and SPRED2 (Gene) is upregulated by Clopidogrel (Compound)
Vitamin E may cau... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.